Eli Lilly & Co. Inc.'s stock (LLY) rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

LSU football was handed a gut-wrenching loss in Week 11 by No. 11 Alabama, a loss that significantly impacted its College Football Playoff odds and path. Already dealing with a small room for ...

Flashes of Navy and Gold ran all over Florida State football as Notre Dame handed the Seminoles a 52-3 loss Saturday night. In front of a nearly sold-out Notre Dame Stadium, the Fighting Irish (8 ...